AstraZeneca PLC
US President Donald Trump has announced a deal with AstraZeneca PLC that will lead to significantly lower domestic drug prices in exchange for granting the pharma giant tariff relief. The agreement requires AstraZeneca to charge "Most Favored Nation" pricing to Medicaid, the US health insurance programme for low-income
AstraZeneca PLC
US President Donald Trump announced that AstraZeneca will offer major discounts on its prescription drugs sold in the US, citing the "most favored nation" pricing clause. This means that Americans will pay the lowest price for AstraZeneca's drugs globally. Trump also revealed that AstraZeneca will invest
AstraZeneca PLC
AstraZeneca, one of the world's largest pharmaceutical companies, is poised to announce a drug pricing deal with President Trump, following a similar agreement made with Pfizer last week. The deal is expected to be disclosed at a White House event later Friday, although details remain unclear. This move
AstraZeneca PLC
President Donald Trump has announced that pharmaceutical company AstraZeneca will offer its prescription medications to the Medicaid program at the lowest prices available anywhere in the world, as part of the administration's effort to lower drug prices and reduce the burden on American taxpayers. This deal, which is
Vaccines
Astrazeneca's groundbreaking research on COVID-19 antibodies has sparked a new approach to vaccine development, allowing for unprecedentedly accelerated production timelines. By leveraging cutting-edge technology and agile workflows, the company expedited the process from discovery to global regulatory approvals in under six months, a feat that typically takes close
Vaccines
AstraZeneca, Britain's most valuable public company, has put on hold a planned £200 million investment in its Cambridge research site, a move that raises further concerns about the UK's life sciences strategy. This decision comes on the heels of AstraZeneca's earlier scrapping of a
Vaccines
The British pharmaceutical giant, AstraZeneca, has paused its planned £200 million expansion of its research site in Cambridge, amid recent news of scrapped plans to invest £450 million in a vaccine plant in Merseyside. This development comes as a blow to the Government, which had been seeking to showcase its
Vaccines
British drug giant AstraZeneca has paused a £200m investment in its Cambridge research facility after a dispute with the Government over NHS charges. The move comes as the company joins a growing list of pharmaceutical businesses frustrated with the UK's increasingly challenging environment for investment. AstraZeneca's
AstraZeneca PLC
A recent study published in Vaccine: X has evaluated the comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children across 13 European countries and the US during the 2019-2023 influenza seasons. The research, conducted by AstraZeneca, aimed to assess the vaccine effectiveness (VE) of
AstraZeneca PLC
AstraZeneca's robust second-quarter and half-year results have reinforced the pharmaceutical group's full-year guidance for 2025. The company's strong revenue growth, core earnings per share, and late-stage trial successes across its research and development pipeline have contributed to its confidence in meeting its financial targets.
AstraZeneca PLC
AstraZeneca, Britain's most valuable public company, may be considering a move of its listing to the United States, a development that has raised concerns among government officials and industry experts. The company's plans to relocate its UK base from Cheshire to a new £1.1 billion
AstraZeneca PLC
Induct AS has announced that AstraZeneca has decided to accelerate the initiation of commercial discussions related to their strategic collaboration, marking a significant milestone for the company. The discussions aim to develop a concrete framework for the rollout of Induct's care pathway for severe asthma in the UK
